Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANP001B
- Development stage
- Unknown
- Lead developer
- ANP Technologies
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ANP001B is a proprietary, nano-encapsulating polymer-based drug delivery platform developed by ANP Technologies. It is designed as a 'Plug and Play' excipient to improve the solubility, pharmacokinetics, safety, and biodistribution of various active pharmaceutical ingredients (APIs), particularly those that are poorly soluble. The platform has been successfully utilized in the chemotherapy drug FID-007 (a nanoparticle formulation of paclitaxel) for the treatment of solid tumors in clinical trials. ANP001B is administered via intravenous injection and its Drug Master File (DMF #36513) was accepted by the U.S. FDA in June 2022.
Beyond the preview
Go deeper on ANP001B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANP001B.